UW Madison UW School of Medicine and Public Health
UW Biiostatistics & Medical Informatics UW Biostatistics & Medical Informatics UW Madison UW Biostatistics & Medical Informatics Site Map

KyungMann Kim

KyungMann Kim

Professor, Departments of Biostatistics & Medical Informatics and Statistics

PhD, 1985, Statistics, University of Wisconsin-Madison

K6/438 Clinical Sciences Center
600 Highland Avenue
Madison, WI 53792-4675

Phone: 608-265-6380
Fax: 608-265-5579

Email:

 
Research Interests

Sequential methods of statistical analysis; clinical trials methodology; categorical data analysis; survival analysis; repeated measures analysis; applications in cancer research; applications in ophthalmology; interface between statistics and computer science

 
Selected Publications

Kim K, DeMets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika 74:149-154, 1987.

Kim K, DeMets DL. Confidence intervals following group sequential tests in clinical trials. Biometrics 43:857-864, 1987.

Kim K. Improved approximation for estimation following closed sequential tests. Biometrika 75:121-128, 1988.

Kim K. Point estimation following group sequential tests. Biometrics 45:613-617, 1989.

Kim K, Tsiatis AA. Study duration for clinical trials with survival response and early stopping rule. Biometrics 46:81-92, 1990.

Cummings FJ, Kim K, Neiman RS, Comis RL, Oken MM, Weitzman SA, Mann RB, O'Connell MJ. Phase II trial of Pentaostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 9:565-571, 1991.

Hochster HS, Kim K, Green MD, Mann RB, Neiman RS, Oken MM, Cassileth PA, Stott P, Ritch P, O'Connell MJ. Activity of Fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992.

Kim K, DeMets DL. Sample size determination for group sequential clinical trials with immediate response. Statistics in Medicine 11:1391-1399, 1992.

Kim K. Study duration for group sequential clinical trials with censored survival data adjusting for stratification. Statistics in Medicine 11: 1477-88, 1992.

Miller, KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ. The evaluation of low dose cytarabine in the treatment of myelodysplastic syndromes: A phase III intergroup study. Annals of Hematology 65: 162-68, 1992.

Borden EC, Kim K, Ryan L, Blum RH, Shiraki M, Tormey DC, Comis RL, Hahn RG, Parkinson DR. Phase II trials of interferons a and -b in advanced sarcomas. J of Interferon Research 12: 455-58, 1992.

Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of Taxol, Merbarone, and Piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Nat Cancer Inst 85: 388-94, 1993.

Loehrer PJ, Kim K, Aisner SC, Livingston R, Johnson D, Blum R. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial. J of Clin Oncol, 12:1164-68, 1994.

Lipsitz SR, Kim K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Statistics in Medicine 13: 1149-63, 1994.

Tsiatis AA, Boucher H, Kim K. Sequential methods for parametric survival models. Biometrika 82: 165-173, 1995.

Kim K. SEQPWR and SEQOPR: Computer programs for power calculations and operating characteristics in maximum information trials. Computer Methods and Programs in Biomedicine 146: 143-153, 1995.

Kim K. A bivariate cumulative probit regression model for ordered categorical data. Statistics in Medicine 14:1341-1352, 1995.

Kim K, Boucher H, Tsiatis AA. Design and analysis of group sequential logrank tests in maximum duration versus information trials. Biometrics 51:988-1000, 1995.

Williamson JM, Kim K, Lipsitz SR. Analyzing bivariate ordinal data using a global odds ratios. J of the Amer Statistical Assoc. 90:1432-37, 1995.

Abrahamsson PA, Adami HO, Taube A, Kim K, Zelen M. RE: Long-term survival and mortality in prostate cancer treatment with noncurative intent by Aus G, Hugosson J, Norlen L. J of Urology 155(1):296-8, 1996 (Jan).

Gale RP, Horowitz MM, Rees JKH, Gray RG, Oken MM, Estey EH, Kim K, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10(1):13-19, 1996 (Jan).

Williamson JM, Kim K. A global odds ratio regression model for bivariate ordered categorical data from ophthalmological studies. Statistics in Medicine 15(14):1507-18, 1996 (Jul 30).

Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial (E1592). J of Clin Oncol 14(8):2345-52, 1996 (Aug).

Lee SJ, Kim K, Tsiatis AA. Repeated significance testing in longitudinal clinical trials. Biometrika 83(4):779-89, 1996.

Goh M, Kleer CG, Kielczewski P, Wojno KJ, Kim K, Oesterling JE. Autologous blood donation prior to anatomical radical retropubic prostatectomy: Is it necessary? Urology 49:569-574, 1997.

Roberts JA, Jenison EL, Kim K, Clark-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67:172-177, 1997.

Loehrer PJ, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D. Cisplatin, doxorubicin and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial. J Clin Oncol 15:3093-3099, 1997.

Wolber FM, Curtis JL, Milik AM, Fields T, Seitzman GD, Kim K, Kim S, Sonstein J, Stoolman LM. Lymphocyte recruitment and the kinetics of adhesion receptor expression during the pulmonary immune response to particulate antigen. Amer J Pathol 151:1715-1727, 1997.

Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Blum R. Randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group study (EST 1587). Cancer 82:292-300, 1998.

Johnson DH, Chang AY, Ettinger DS, Kim K, Bonomi P. Recent advances with chemotherapy in NSCLC: The ECOG experience. Oncology 12 (1 Suppl 2):67-70, 1998

Williamson JM, Lipsitz SR, Kim K. GEECAT and GEEGOR: SAS macro for analysis of correlated categorical response data. Computer Methods and Programs in Biomedicine 58:25-34, 1999.

Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice daily thoracic radiotherapy versus once daily thoracic radiotherapy in limited small-cell lung cancer treated with concurrently with cisplatin-etoposide chemotherapy. New England Journal of Medicine 340:265-271, 1999.

Book chapters

Bennett JM, Miller KB, Kim K, Morrison FS, Winter JN, Cassileth P, Neiman RS, Head D. Phase III evaluation of low-dose cytosine arabinoside versus supportive care in the treatment of adults with myelodysplastic syndrome: An intergroup study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group-- preliminary results. In Schmalzl F, Mufti GJ (eds.) Myelodysplastic Syndromes. Berlin: Springer-Verlag, 1992:253-258.

Propert KJ, Kim K. Group sequential methods in multi-institutional cancer trials: a case study. In Peace KE (ed.), Biopharmaceutical Sequential Statistical Applications. New York: Marcel Dekker, 1992:133-153.

Kim K, Lipsitz SR, Williamson JM. Regression models for bivariate ordered categorical data from ophthalmological studies. In Koo JY, Park BU, Lee KW, Jeon JW (eds). Collected Papers in Honor of Retirement of Professor Chung Han Yung. Seoul National University, Department of Computer Science and Statistics Alumni Association, 1996:36-55.

Search PubMed for other publications by KyungMann Kim

 

 
Sailboats at Sunset UW Residence Halls UW West Campus UW Armory Building UW Observatory Hill